Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit

Sambrook, Philip N.; Seeman, Ego; Phillips, Stephen; Ebeling, Peter R.

doi:10.5694/j.1326-5377.2002.tb04475.x

Cited by 56 publications

(73 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study in addition to others have shown that bone loss is greatest from the proximal femur in the first year post‐alloHSCT (8.5–12%) compared with 3–5.9% at the spine 3 . Decreases in BMD of this magnitude would be anticipated to more than double the relative risk for fractures by analogy with findings in postmenopausal osteoporosis 4 . The incidence of fragility fractures has been poorly studied in this context.…”

Section: Variables Relating To Patient Demographics Glucocorticoid Dmentioning

confidence: 49%

Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation

D'Souza

Grigg

Szer

et al. 2006

Internal Medicine Journal

View full text Add to dashboard Cite

Allogeneic haemopoietic stem cell transplant (alloHSCT) patients are at increased risk of osteoporosis. Zoledronic acid (ZA) is a potent i.v. bisphosphonate; however, there are few data on ZA use after alloHSCT. The aim of this study is to examine the effect of a single 4 mg ZA infusion in alloHSCT patients with either osteoporosis (T-score < -2.5) or rapid bone loss post-alloHSCT. An uncontrolled, prospective study of 12 consecutive patients receiving ZA, predominantly within the first year post-HSCT. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry at the spine and proximal femur pretransplant, pre-ZA and post-ZA. The median annualized percentage change in total hip BMD between the pretransplant scan and the scan immediately before ZA was -13% (range, -51 to +3.6%). After ZA treatment, the total hip BMD increased by a median of +3.3% (range, -20.4 to +14.8%) in 75% of patients. The median annualized percentage change in femoral neck BMD between the pretransplant scan and the scan immediately before ZA was -13.2% (range, -40 to +1.0%). Post-ZA, femoral neck BMD increased by a median of +1.4% (range, -22.2 to +33.6%). Only one patient continued to lose bone from the femoral neck post-ZA infusion. The median annualized percentage change in spinal BMD pretransplant was -12.5% (range, -38 to +6.9%). Post-ZA, spinal BMD decreased by a median of -2.8% (range, -27.6 to +24.4%). Four patients continued to lose bone from the spine post-ZA. ZA reduces bone loss in most patients after alloHSCT. Our data require confirmation in a larger prospective, randomized study.

show abstract

Section: Variables Relating To Patient Demographics Glucocorticoid Dmentioning

confidence: 49%

Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation

D'Souza

Grigg

Szer

et al. 2006

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…It is estimated that osteoporosis affects up to 75 million people in Europe, the United States, and Japan, with 33% of women and 20% of men suffering bone fracture as a result 2. These figures are similar to other western countries like Australia where currently 25% of women and 17% of men will develop osteoporotic‐related fractures 3. With the advent of dual‐energy x‐ray absorptiometry (DEXA), bone density testing has become commonplace in the postmenopausal and elderly populations.…”

supporting

confidence: 60%

Bone Loss in Crohnʼs Disease: Exercise As a Potential Countermeasure

Lee

Radford‐Smith

Taaffe

2005

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Crohn's disease (CD) is associated with a number of secondary conditions including osteoporosis, which increases the risk of bone fracture. The cause of metabolic bone disease in this population is believed to be multifactorial and may include the disease itself and associated inflammation, high-dose corticosteroid use, weight loss and malabsorption, a lack of exercise and physical activity, and an underlying genetic predisposition to bone loss. Reduced bone mineral density has been reported in between 5% to 80% of CD sufferers, although it is generally believed that approximately 40% of patients suffer from osteopenia and 15% from osteoporosis. Recent studies suggest a small but significantly increased risk of fracture compared with healthy controls and, perhaps, sufferers of other gastrointestinal disorders such as ulcerative colitis. The role of physical activity and exercise in the prevention and treatment of CD-related bone loss has received little attention, despite the benefits of specific exercises being well documented in healthy populations. This article reviews the prevalence of and risk factors for low bone mass in CD patients and examines various treatments for osteoporosis in these patients, with a particular focus on physical activity.

show abstract

“…Osteoporosis and aging increase the likelihood of bone fracture (Kanis et al, 2001; Lewiecki, 2004), and given the costs and co-morbidity associated with bone fractures, this increase is a major health concern in the US (Ray et al, 1997) as well as other countries (Levy et al, 2002; Lippuner et al, 2005; Sambrook et al, 2002). While low areal bone mineral density (BMD) as determined by dual-energy X-ray absorptiometry (DXA) can be an important risk factor for fracture susceptibility, age alone significantly and independently contributes to fracture risk (Johnell et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Raman and mechanical properties correlate at whole bone- and tissue-levels in a genetic mouse model

Patil

Lynch

et al. 2011

Journal of Biomechanics

View full text Add to dashboard Cite

The fracture resistance of bone arises from the composition, orientation, and distribution of the primary constituents at each hierarchical level of organization. Therefore, to establish the relevance of Raman Spectroscopy (RS) in identifying differences between strong or tough bone and weak or brittle bone, we investigated whether Raman-derived properties could explain the variance in biomechanical properties at both the whole bone and the tissue-level, and do so independently of traditional measurements of mineralization. We harvested femurs from wild-type mice and mice lacking matrix metalloproteinase 2 because the mutant mice have a known reduction in mineralization. Next, RS quantified compositional properties directly from the intact diaphysis followed by micro-computed tomography to quantify mineralization density (Ct.TMD). Correlations were then tested for significance between these properties and the biomechanical properties as determined by the three point bending test on the same femurs. Harvested tibia were embedded in plastic, sectioned transversely, and polished in order to acquire average Raman properties per specimen that were then correlated with average nanoindentation properties per specimen. Dividing the ν 1 phosphate by the proline peak intensity provided the strongest correlation between the mineral-to-collagen ratio and the biomechanical properties (whole bone modulus, strength and post-yield deflection plus nanoindentation modulus). Moreover, the linear combination of ν 1 phosphate/proline and Ct.TMD provided the best explanation of the variance in Correspondence: Jeffry S. Nyman, Vanderbilt Orthopaedic Institute, Medical Center East, South Tower, Suite 4200, Nashville, TN, 37232, Tel: (615) 936-6296, Fax: (615) 936-0117, jeffry.s.nyman@vanderbilt.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. CONFLICT OF INTEREST STATEMENTNone of the authors have a conflict of interest related to the research described in this manuscript. The study sponsor had no involvement in the study design, in the collection of data, and the subsequent analysis and interpretation of the results. strength between the genotypes, and it alone was the best explanatory variable for brittleness. Causal relationships between Raman and fracture resistance need to be investigated, but Raman has the potential to assess fracture risk. NIH Public Access

show abstract

Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit

Cited by 56 publications

References 120 publications

Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation

Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation

Bone Loss in Crohnʼs Disease: Exercise As a Potential Countermeasure

Raman and mechanical properties correlate at whole bone- and tissue-levels in a genetic mouse model

Contact Info

Product

Resources

About